Covid-19

#Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Vaccines

GSK to support manufacture of Novavax’ Covid-19 vaccine

Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ Covid-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide… Read More

#Covid-19 #News

#Antibodies #Covid-19 #Online focus

Putting function first to find antibodies against difficult target

Three case studies from Berkeley Lights The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Berkeley Lights has established multiple partnerships worldwide to provide access to its platform to rapidly accelerate the… Read More

#Covid-19 #News

#Covid-19 #Drug development #Immunology / Virology & Vaccines #Research

Modelling and simulation facilitates drug repurposing to counter Covid-19

By Dr Craig R. Rayner, FRCP Edin, PharmD, MBA, President, Integrated Drug Development at Certara Right at the start of the Covid-19 pandemic, medical researchers began questioning whether there were any existing, on-market drugs that might prove effective against SARS-CoV-2. They wanted to offer healthcare professionals and patients some known… Read More

#Business & Investment #Exclusive Content #News

#Biotechnology #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Pharma #Vaccines

The effect of Covid-19 solutions on the clinical trials process

Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases at ICON, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership. The world responded to the Covid-19 crisis at unprecedented speed — including vaccine development. During a pandemic, timing… Read More

#Business & Investment #Covid-19 #Exclusive Content #News

#Cancer research #Covid-19 #Immunology / Virology & Vaccines #Research

Cancer drug lessens toxicity of protein from virus that causes Covid-19

The University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2 and then used an FDA-approved cancer drug to blunt the viral protein’s detrimental effects. In experiments in fruit flies and human cell lines, the team discovered the cell process that the virus… Read More

#Cancer Research #Covid-19 #News

#Assays #Biologics / Biotechnology #Covid-19 #Data

GSK and Vir Biotechnology request for EUA for COVID-19 treatment

GlaxoSmithKline (GSK) and Vir Biotechnology have announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorisation (EUA) for VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and older weighing at least 40… Read More

#Covid-19 #News

#Biotherapeutics #Coronavirus #Covid-19 #Drug development

Infex filed for UK patent for coronavirus novel therapy design

Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains. The COV-X program targets a protein which is essential for viral replication across a broad spectrum of related coronaviruses, including SARS-CoV-1, MERS-CoV and SARS-CoV-2. If successfully developed, the treatment aims to form… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug development #Drug discovery #Research

Hormone drugs may disarm COVID-19 spike protein

Researchers in the Abramson Cancer Center at the University of Pennsylvania have published a new preclinical study which found hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease. The study, published online in Cell Press’s iScience, showed how two… Read More

#Covid-19 #News

#AstraZeneca #Clinical trial #Covid-19 #Immunology / Virology & Vaccines

Oxford-AstraZeneca US vaccine trial data may be outdated

The Data and Safety Monitoring Board (DSMB) has notified the National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority (BARDA), and AstraZeneca that it is “concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial”. Trial volunteers received two standard… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibodies #Biologics #Covid-19 #Drug development #Drug discovery #Online focus

IONTAS has identified novel SARS-CoV-2 neutralising antibodies

IONTAS and FairJourney Biologics have identified neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalised COVID-19 patients, identified potent neutralising antibodies with distinct mechanisms of action. Based on this approach, the company has… Read More

#News

#AstraZeneca #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

US trial data show Oxford-AstraZeneca vaccine is safe and 79% effective 

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca in the US, Chile and Peru has shown that the vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom. In the trial, which… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biotechnology #Covid-19 #Drug development

Molecular ‘cookie cutter’ method could provide key for COVID drug discovery

Researchers from the University of Birmingham are working to isolate and extract the COVID-19 encounter complex in a form that is stable enough for identification of target sites for future anti-viral drugs. The encounter complex is formed when the COVID-19 spike latches onto a binding site on an ACE-2 receptor,… Read More

#News

#AstraZeneca #Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pfizer

Existing vaccines may protect against coronavirus variants

Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise or stop infection from variants that are circulating in South Africa, Brazil and elsewhere. The data suggests that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly,… Read More

#Covid-19 #News

#Biopharmaceutical #Covid-19 #Immunology / Virology & Vaccines #Sputnik

RDIF and Stelis Biopharma partner to vaccinate 100 million with Sputnik V

The Russian Direct Investment Fund (RDIF) and Stelis Biopharma, the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against COVID-19, sufficient to vaccinate 100 million people. Sputnik V is now approved for… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Cell and protein analysis #Covid-19 #Immunology / Virology & Vaccines #Podcast

Advances in cell and protein analysis for virology research – podcast

This exclusive podcast features Dr Hongshan Li, Applications Manager, Sartorius, discussing advances in cell and protein analysis for virology research. This episode examines virology research – what’s currently happening in the sector and how new advances in technology are helping push forward innovation and drug development. With COVID-19 playing such… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Podcast #Sartorius

Advances in cell and protein analysis for virology research

This free to listen podcast and DDW exclusive, features Dr Hongshan Li, Applications Manager, Sartorius, discussing advances in cell and protein analysis for virology research. This episode only available to download here, examines virology research – what’s currently happening in the sector and how new advances in technology are helping push forward… Read More

#Podcasts